Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia

SIMPLE SUMMARY: Non-covalent Bruton’s tyrosine kinase inhibitors (ncBTKi) are being investigated for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL). These agents hold promise for the treatment of CLL, especially CLL requiring treatment after prior discontinuation...

Descripción completa

Detalles Bibliográficos
Autores principales: Montoya, Skye, Thompson, Meghan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377484/
https://www.ncbi.nlm.nih.gov/pubmed/37509309
http://dx.doi.org/10.3390/cancers15143648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377484/
https://www.ncbi.nlm.nih.gov/pubmed/37509309
http://dx.doi.org/10.3390/cancers15143648

Ejemplares similares